Five things for pharma marketers to know: Wednesday, March 7, 2018

Share this content:

The FDA has given 23andMe the okay for at-home tests for breast cancer. The kits examine whether customers have any of three breast cancer gene mutations. (CNN) However, the FDA warned that the test detects very few breast cancer gene mutations. (NBC News)


Novartis and technology company Science 37 are teaming up on virtual clinical trials in which patients participate via mobile device. Off-site trials have begun for cluster headaches and NASH. Novartis was an early investor in Science 37. (Endpoints News)


The top medicine regulator in Europe has called for the suspension of multiple sclerosis drug Zinbryta after a dozen reports of inflammation of the brain, including three fatal cases. Drugmakers Biogen and AbbVie recalled the drug last week. (Reuters)


The FDA has approved Trogarzo, a treatment for HIV patients who are resistant to multiple other treatments. The drug is made by Taiwanese company TaiMed. It requires intravenous use once every 14 days in combination with other treatments. (FiercePharma)


The Department of Veterans Affairs' internal watchdog has found that Secretary David Shulkin did not fix issues with dirty syringes and equipment when he was a top VA official in the Obama administration. The report determined there was a “culture of complacency” at the department. (Associated Press)


Share this content:
Scroll down to see the next article